Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.95
WX's Cash to Debt is ranked higher than
65% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. WX: 4.95 )
WX' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 4.95

Equity to Asset 0.77
WX's Equity to Asset is ranked higher than
83% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. WX: 0.77 )
WX' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.8
Current: 0.77

-0.32
0.8
F-Score: 6
Z-Score: 9.10
M-Score: -2.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Revenue Growth (%) 21.20
WX's Revenue Growth (%) is ranked higher than
95% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. WX: 21.20 )
WX' s 10-Year Revenue Growth (%) Range
Min: 10.8   Max: 159.6
Current: 21.2

10.8
159.6
EBITDA Growth (%) 13.20
WX's EBITDA Growth (%) is ranked higher than
90% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. WX: 13.20 )
WX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 102.7
Current: 13.2

0
102.7
EPS Growth (%) 8.80
WX's EPS Growth (%) is ranked higher than
89% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. WX: 8.80 )
WX' s 10-Year EPS Growth (%) Range
Min: 0   Max: 45
Current: 8.8

0
45
» WX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

WX Guru Trades in Q1 2013

John Hussman 40,000 sh (New)
Jim Simons 45,900 sh (New)
Caxton Associates 25,100 sh (+2.87%)
Mario Gabelli 128,600 sh (-2.28%)
Julian Robertson 1,036,618 sh (-10.2%)
Manning & Napier Advisors, Inc 203,970 sh (-81.86%)
» More
Q2 2013

WX Guru Trades in Q2 2013

Ron Baron 11,000 sh (New)
Columbia Wanger 2,708,477 sh (New)
Steven Cohen 151,806 sh (New)
John Hussman 40,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Caxton Associates Sold Out
Mario Gabelli 117,100 sh (-8.94%)
Julian Robertson 891,618 sh (-13.99%)
Jim Simons 29,400 sh (-35.95%)
» More
Q3 2013

WX Guru Trades in Q3 2013

Sarah Ketterer 106,600 sh (New)
Jim Simons 95,100 sh (+223.47%)
Ron Baron 17,000 sh (+54.55%)
Columbia Wanger 3,002,365 sh (+10.85%)
Mario Gabelli 86,600 sh (-26.05%)
Julian Robertson 576,218 sh (-35.37%)
John Hussman 20,000 sh (-50%)
Steven Cohen 66,700 sh (-56.06%)
» More
Q4 2013

WX Guru Trades in Q4 2013

Ron Baron 167,200 sh (+883.53%)
Jim Simons 151,000 sh (+58.78%)
Sarah Ketterer 138,400 sh (+29.83%)
Julian Robertson Sold Out
Steven Cohen Sold Out
Columbia Wanger 2,983,877 sh (-0.62%)
Mario Gabelli 65,200 sh (-24.71%)
John Hussman 10,000 sh (-50%)
» More
» Details

Insider Trades

Latest Guru Trades with WX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2013-12-31 Sold Out 2.4%$26.52 - $38 $ 35.9714%0
Ron Baron 2013-12-31 Add 883.53%0.02%$26.52 - $38 $ 35.9714%167200
John Hussman 2013-12-31 Reduce -50%0.02%$26.52 - $38 $ 35.9714%10000
Mario Gabelli 2013-12-31 Reduce -24.71%$26.52 - $38 $ 35.9714%65200
Julian Robertson 2013-09-30 Reduce -35.37%0.85%$20.23 - $28.48 $ 35.9752%576218
John Hussman 2013-09-30 Reduce -50%0.02%$20.23 - $28.48 $ 35.9752%20000
Mario Gabelli 2013-09-30 Reduce -26.05%$20.23 - $28.48 $ 35.9752%86600
Ron Baron 2013-09-30 Add 54.55%$20.23 - $28.48 $ 35.9752%17000
Julian Robertson 2013-06-30 Reduce -13.99%0.34%$16.94 - $21.54 $ 35.9784%891618
Ron Baron 2013-06-30 New Buy$16.94 - $21.54 $ 35.9784%11000
John Hussman 2013-03-31 New Buy0.03%$15.44 - $17.91 $ 35.97118%40000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on WuXi PharmaTech (Cayman) Inc

Baron Funds Comments on WuXi PharmaTech - Feb 24, 2014

Shares of WuXi PharmaTech (Cayman) Inc. (WX) were strong in the fourth quarter. As the largest Chinese Contract Research Organization (CRO), with an estimated 27% market share, WuXi is a beneficiary of increased pharma outsourcing activity to countries like China and India. Performance during the fourth quarter is attributable to above consensus financial results and a growing pipeline of contract research and manufacturing activity. We retain conviction in the company due to its high growth potential and strong relationships with leading pharmaceutical companies. (Anuj Aggarwal)

From Ron Baron (Trades, Portfolio)'s Baron Funds' fourth quarter 2013 commentary.

Check out Ron Baron latest stock trades

Top Ranked Articles about WuXi PharmaTech (Cayman) Inc

Baron Funds Comments on WuXi PharmaTech
Shares of WuXi PharmaTech (Cayman) Inc. (WX) were strong in the fourth quarter. As the largest Chinese Contract Research Organization (CRO), with an estimated 27% market share, WuXi is a beneficiary of increased pharma outsourcing activity to countries like China and India. Performance during the fourth quarter is attributable to above consensus financial results and a growing pipeline of contract research and manufacturing activity. We retain conviction in the company due to its high growth potential and strong relationships with leading pharmaceutical companies. (Anuj Aggarwal) Read more...
Columbia Management's Top 5 New Buys with Positive Outlook
As one of the 10 largest management firms in the U.S., Columbia Management Investment Advisers oversees $300 billion in a variety of mutual funds, closed-end funds and other products. The firm announced 24 new stock positions made in the second quarter, bringing about a 5% turnover in its portfolio totaling 310 stocks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.40
WX's P/E(ttm) is ranked higher than
69% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.90 vs. WX: 22.40 )
WX' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 103.94
Current: 22.4

6.67
103.94
P/B 3.40
WX's P/B is ranked higher than
65% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. WX: 3.40 )
WX' s 10-Year P/B Range
Min: 1.11   Max: 10.64
Current: 3.4

1.11
10.64
P/S 4.53
WX's P/S is ranked higher than
59% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. WX: 4.53 )
WX' s 10-Year P/S Range
Min: 0.79   Max: 11.05
Current: 4.53

0.79
11.05
PFCF 21.70
WX's PFCF is ranked lower than
152% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.94 vs. WX: 21.70 )
WX' s 10-Year PFCF Range
Min: 15.21   Max: 52.89
Current: 21.7

15.21
52.89
EV-to-EBIT 21.30
WX's EV-to-EBIT is ranked higher than
56% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.60 vs. WX: 21.30 )
WX' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 146.9
Current: 21.3

8.3
146.9
PEG 1.20
WX's PEG is ranked higher than
98% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. WX: 1.20 )
WX' s 10-Year PEG Range
Min: 0.08   Max: 1.2
Current: 1.2

0.08
1.2
Shiller P/E 33.80
WX's Shiller P/E is ranked higher than
72% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.47 vs. WX: 33.80 )
WX' s 10-Year Shiller P/E Range
Min: 18.26   Max: 64.93
Current: 33.8

18.26
64.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.40
WX's Price/Net Cash is ranked lower than
59% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. WX: 14.40 )
WX' s 10-Year Price/Net Cash Range
Min: 11.88   Max: 28.13
Current: 14.4

11.88
28.13
Price/Net Current Asset Value 8.70
WX's Price/Net Current Asset Value is ranked higher than
57% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.65 vs. WX: 8.70 )
WX' s 10-Year Price/Net Current Asset Value Range
Min: 5.91   Max: 1193
Current: 8.7

5.91
1193
Price/Tangible Book 3.70
WX's Price/Tangible Book is ranked higher than
70% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. WX: 3.70 )
WX' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 9.09
Current: 3.7

1.45
9.09
Price/DCF (Projected) 2.80
WX's Price/DCF (Projected) is ranked lower than
51% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. WX: 2.80 )
WX' s 10-Year Price/DCF (Projected) Range
Min: 1.81   Max: 4.82
Current: 2.8

1.81
4.82
Price/Median PS Value 1.70
WX's Price/Median PS Value is ranked lower than
54% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. WX: 1.70 )
WX' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 3.29
Current: 1.7

0.35
3.29
Price/Peter Lynch Fair Value 1.20
WX's Price/Peter Lynch Fair Value is ranked higher than
90% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. WX: 1.20 )
WX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.25   Max: 0.75
Current: 1.2

0.25
0.75
Price/Graham Number 1.90
WX's Price/Graham Number is ranked higher than
66% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. WX: 1.90 )
WX' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 4.93
Current: 1.9

0.86
4.93
Earnings Yield (Greenblatt) 4.70
WX's Earnings Yield (Greenblatt) is ranked higher than
65% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. WX: 4.70 )
WX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 12
Current: 4.7

0.7
12
Forward Rate of Return (Yacktman) 18.92
WX's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.75 vs. WX: 18.92 )
WX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 28.4   Max: 156
Current: 18.92

28.4
156

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:3W11.Germany
WuXi PharmaTech (Cayman), Inc., is a Cayman Islands holding company. It conducts substantially all of its business through five operating subsidiaries in China and one operating subsidiary in the United States. It is a pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. It provides a broad and integrated portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include many of the world's premier pharmaceutical, biotechnology and medical device companies. The Company's services are designed to assist its global customers in shortening the time and lowering the cost of pharmaceutical and medical-device R&D by providing cost-effective and efficient outsourcing solutions. It groups its operations into two segments: laboratory services and manufacturing services. The Company's laboratory services segment focused entirely on helping its customers discover and develop small-molecule pharmaceuticals through its services in discovery chemistry, medicinal chemistry, service biology, toxicology, formulation and bioanalytical and analytical services. The Company's manufacturing services segment focused on producing advanced intermediates and APIs for small-molecule pharmaceuticals used by its customers in clinical testing. Laboratory services are composed of discovery chemistry, discovery biology, DMPK/ADME, toxicology, process R&D, formulation, bioanalytical, biologics testing, medical device testing and development, and other related contract R&D services. The Company's current customers include all of the world's ten largest pharmaceutical companies. The pharmaceutical and biotechnology R&D outsourcing market remains highly fragmented. It competes with industry players in particular service areas- for example with Charles River Laboratories International, Inc., which recently partnered with Shanghai BioExplorer Co., Ltd., in the preclinical services area, and with Shanghai ChemPartner Co., Ltd. and BioDuro in the discovery chemistry area. Governmental agencies throughout the world, particularly in the United States, strictly regulate the pharmaceutical, biotechnology and medical device R&D process.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide